^
Association details:
| Biomarker: | SMARCB1 mutation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Published date:
05/18/2023
Excerpt:
The most frequently mutated gene was TP53 in both groups followed by VHL in trastuzumab-sensitive patients and ATM in trastuzumab-resistant group...On the other hand, MLH1, SMARCB1, and SMO genes were only mutated in the resistant group....NGS sequencing is a useful tool to detect genetic variants that could predict response to trastuzumab therapy.
DOI:
10.1186/s40246-023-00493-5
